NCT06504992View on ClinicalTrials.gov

Powdered Intrawound Vancomycin in Open Fractures Trial

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

350

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2029

Conditions

Open FractureTraumaInfection, Surgical SiteFractures, OpenWound InfectionFractures, BonePost-Operative Wound Infection

Interventions

DRUG

Vancomycin 1000 MG

Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement

Trial Locations (1)

R3A 1R9

Health Sciences Centre Winnipeg, Winnipeg

All Listed Sponsors

collaborator

Health Sciences Centre, Winnipeg, Manitoba

OTHER

lead

University of Manitoba

OTHER

NCT06504992 - Powdered Intrawound Vancomycin in Open Fractures Trial | Biotech Hunter | Biotech Hunter